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Acceptance of new tests that are alternatives to currently used toxicology tests is a topic of
considerable importance in the field of toxicology. Carcinogenicity testing today normally includes
2-year studies in rats and mice of both sexes, following widely accepted procedures for
husbandry; selection of dose levels; pathology and toxicity observations; and statistical
interpretation of tumor data. These studies are usually preceded by tests for genetic toxicity and
subchronic toxicity studies to select dose levels for the 2-year studies. Although these data are
used for quantitative risk assessment, the mechanistic basis for effects is usually unknown. The
series of studies is very expensive and requires 5 years or more to conduct. Alternative
approaches are being developed that would provide more mechanistic information and hopefully
would permit decisions to be made about carcinogenic potential without the need to conduct 2-
year studies in rats and mice of both sexes. Decisions could be based on a profile of data rather
than on the result of one test. Procedures for regulatory acceptance of new approaches for
carcinogenicity testing are critical to future progress. Environ Health Perspect 106(Suppl
2):467-471 (1998). http://ehpnetl.niehs.nih.gov/docs/1998/Suppl-2/467-471schwetz/
abstract.html
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Introduction
Acceptance of alternative tests represents
an opportunity to introduce new test
methods into the toxicologist's armamen-
tarium that will eventually reduce our
dependence on resource-intensive whole
animal tests. New test designs must be sen-
sitive to the desire for mechanistically
based data and the "three Rs"-reduction
of the number of animals, refinements to
enhance the well-being of animals, and
replacements that do not use whole ani-
mals or lower species. This paper presents a
strategy for using alternative tests for car-
cinogenesis screening. The term carcinogen
is used here in the broad sense as an agent
capable ofincreasing the incidence ofmalig-
nant neoplasia after exposure. The concepts
underlying the strategy apply to other areas
of toxicology in which commonly used
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in vivo tests can be potentially replaced by
alternative tests.
It has been suggested for some time that
the use of the 2-year rodent bioassay as a
screen, not as a definitive study for carcino-
genic potential, but only as a screen. The
reason for this has been that the 2-year
bioassay as currently conducted is approxi-
mately one million dollars per study (single
sex-species combination) and frequently
gives equivocal results. Consequently, this is
an expensive and time-consuming screen
that often does not give definitive answers.
This recommendation to seek alternatives
was based on the assumption that the 2-
year bioassay would be replaced with better
test systems that had the desirable charac-
teristics of being cheaper and faster, using
fewer animals, and providing the appropri-
ate sensitivity and specificity desired of a
screen for carcinogenic potential. For many
years, the desire to replace the 2-year rodent
bioassay with other tests was a matter of
talk with very little action to accomplish
that objective. During the past 5 years,
however, there has been clear movement
toward acceptance of some alternatives to
the 2-yearstudy. Presently, one ofthe prob-
lems is the segregation oftoxicologists into
three groups in response to a movement
toward alternative test systems. First, are
those who now recommend no change and
a continuation of 2-year studies in two
species of both sexes when there is a need
for carcinogenicity data. A second group
supports the proposal of the International
Committee for Harmonization for drugs
(1); that is, when carcinogenicity data are
required, the studieswould be conducted in
one rodent species and be supplemented by
other data. The default rodent species
would be the rat. A third group recom-
mends simply conducting carcinogenicity
studies in one species of rodent, preferably
the rat, with no requirement for otherdata.
None ofthese choices is clearly right or
wrong. One of the problems with our
approach over the last two decades is that
we have accepted the standard 2-year bioas-
say, typified by the study design that has
been used by the National Toxicology
Program (NTP) in the past, as the standard
study design for all chemicals, reflecting the
philosophy that "one size fits all." As we
learn more aboutthe modes ofaction ofcar-
cinogens, it becomes clear that some other
alternative must be considered and that the
selection ofstudies must be tailored to the
individual chemical. The choice of tests
should be based on the chemical properties
ofthe substances as well as on the available
biologic and toxicologic data. The nature
and amount of human exposure involved
must also be considered. For example, dif-
ferent tests might be warranted for a food
additive, pesticide, or a substance for which
there is occupational exposure compared to
a drug with a very limited population and
duration ofexposure. The test profile might
be different for a low-level contaminant in a
product compared to the active ingredient.
Rather than simply categorize chemicals as
carcinogens or noncarcinogens, Ames et al.
(2) suggest examining the ratio of antici-
pated human exposure to a dose producing
tumors in rodents.
In this paper we present a strategy to
reduce dependence on 2-year studies for
assessing carcinogenic potential and a
review ofthe 2-year rodent study accepted
as the "gold standard." Progress in accept-
ing alternatives to the 2-year studies
depends, first, on acceptance of a new test
paradigm and, second, on a need to move
away from past tradition ofrequiring 2-year
studies in both sexes of two species every
time carcinogenicity data are required.
These two steps are not as interdependent
as the idea ofreplacement ofagold standard
might suggest.
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Review ofthe2-Year
Rodent Studies
Because acceptance ofalternatives to 2-year
studies will require change, it is important
to identify the constraints of such a
change. The precedent of having required
two-species, 2-year rodent studies has pro-
vided us with a certain level ofcomfort in
knowing what to require when carcino-
genicity data are desired. In addition to the
comfort that rests with that tradition, con-
siderable importance has been attributed to
the historical database. Also, it is human
nature that significant changes are hard to
effect. Both the regulated industry and reg-
ulators knowwhat to expect under the cur-
rent paradigm, what to expect in terms of
testing when it is required and what the
interpretation will be depending on the
outcome of the study. As a result of these
constraints, change has been slow.
Change is required, however. There are
a number ofoften-cited reasons for change
that are obvious, such as the cost of2-year
studies, the use of large numbers of ani-
mals, the duration required to conduct the
studies, and the uncertainty of the out-
come in terms of equivocal answers or
extrapolation of results to humans. For
example, because of the high background
incidence ofliver tumors in male B6C3F1
mice, discussions continue on the relevance
ofthis tumor for humans.
There are some less obvious reasons for
change that must also be pointed out. Two-
year rodent studies are empirical in nature;
the assumption is that the development of
most tumors, even by unknown mecha-
nisms, is predictive of some tumorigenic
potential in humans. Some notable excep-
tions are kidney tumors formed in male rats
due to an accumulation ofthe a2p-globulin
protein and bladder tumors due to the
formation ofcrystals in the urine.
The historical database we have relied
on is not as useful as was assumed. For
example, there has been genetic drift in
many of the strains of animals believed to
be genetically pure strains. The observation
that the bodyweight ofcertain test animals
has increased progressively during the past
few years has complicated the use of con-
trol data (3). Animals live a shorter time
and the profile of tumors is different.
Therefore, control data generated 15 years
ago, when mean bodyweights were consid-
erablyless, cannot be the basis for compari-
sons to studies conducted today in heavier
animals (4). Consequently, we have moved
away from using historical databases to the
use ofcontemporary databases, eliminating
control data from earlieryears. The primary
emphasis is now given to concurrent con-
trol data, again recognizing the fact that
control data from previous years are less
valuable than concurrent control data.
We have been concerned about the
predictivity of2-year bioassays over the last
decade as our experience and knowledge
have expanded. This issue must be
addressed as we consider the benefit of
alternative test systems. New test systems
reflect new scientific developments, that is,
new models that are mechanistically based
and reflect the increasing diversity of
mechanisms that contribute to the devel-
opment ofthe carcinogenic response. Such
information is not obtained from 2-year
rodent studies as they have been conducted
in the past.
One of the evaluative measures of the
2-year studyas agold standard is the predic-
tiveness observed between rats and mice.
The species concordance has been evaluated
and reviewed by many investigators, indud-
ingDiCarlo (5), who reviewed the results of
138 NTP bioassays and found that the
rat-mouse concordance was 75%. More
recently, Huff et al. (6) reviewed the con-
cordance of379 NTP bioassays and found a
74% level of rat-mouse concordance.
Contrera et al. (7) reviewed the results of
282 drugs in the U.S. Food and Drug
Adminstration (U.S. FDA) database and
again found a 74% rat-mouse concordance.
The importance of this observation is that
the U.S. FDA database consists primarily of
studies in Sprague-Dawley rats and Swiss
Webster-derived mice; the NTP database is
based primarily on results from Fischer 344
rats and B6C3F1 mice. The similarity and
concordance in these databases lends valid-
ity to the observation that the numbers
reflect the response of rodent species. It is
difficult to imagine a better predictor ofrat
carcinogenicity than mouse carcinogenicity
or vice versa. The overall concordance,
however, between rats and mice has been
identified repeatedlyasabout75%.
Potency is another measure of the
usefulness of the 2-year rodent studies.
Carcinogenic potency is defined as the life-
time risk per unit of average daily expo-
sure. Exposure is generally expressed as
milligram per kilogram body weight or
concentration in food, water, or air. Target
tissue concentrations are seldom available.
Crouch and Wilson (8) and Crouch (9)
concluded that there was good species
correlation for those chemicals that were
carcinogenic in both rats and mice. The
potencies ofthe two species were generally
within a factor of 20 of each other. Note
that this is true only for chemicals that
were carcinogenic in both species.
Using the carcinogenic potency database
compiled by Gold and co-workers (10) on
770 compounds, Gaylor and Chen (11)
showed good agreement for carcinogenic
potency, on the average, among rats, mice,
and hamsters for various routes ofexposure.
However, variability was substantial, with
differences generally within a factor of 100.
For 69 NTP chemicals that produced
tumors in the same sex and tissue site, Chen
and Gaylor (12) showed that carcinogenic
potencies for rats and mice were generally
within afactor of40. Despite thevariability,
it has been argued that the correlation of
potencies between rats and mice supports
extrapolation to humans. However, the
studies were only conducted on concordant
chemicals, i.e., chemicals that produce
tumors in both rats and mice.
Tennant et al. (13) prospectively
predicted the carcinogenic status of 44
NTP chemicals based upon chemical struc-
ture, Salmonella assay results, dose level,
and subchronic pathology. Wachsman et al.
(14) presented the results oftheTennant et
al. (13) predictions, along with the predic-
tions of seven other groups, with the out-
come for 40 of the chemicals. There was
substantial agreement among the eight pre-
dictive systems on 14 of40 (35%) chemi-
cals that were clearly positive or negative.
Human expert systems performed better
than computer-based systems. There was a
good correlation between electrophilicity
and carcinogenicity. A high percentage of
equivocal results in the 2-year bioassays
makes it difficult to validate predictive sys-
tems. Further, Ashby and Tennant (15)
concluded from this exercise that the inte-
gration ofdifferent predictive techniques is
preferable to the use of single techniques.
They concluded that carcinogenic predic-
tivity appears to be limited to less than
80%. Part ofthe problem is that the 2-year
bioassay cannot detect weak carcinogens,
and high doses may produce carcinogenic-
ity by indirect mechanisms that would not
be predicted at lower dose levels. That is,
the 2-year bioassay cannot always accu-
rately determine the carcinogenicity of a
chemical. Nonetheless, many accept the 2-
year bioassay as the best available test for
carcinogenicity at the present time, despite
the fact that the 2-year bioassay has a
relatively high rate ofnegative condusions
(16). There are questions about the
relevancy of certain tumor types observed
in rodents to humans. This is particularly
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true for very high dose levels of exposure.
Ashby and Purchase (17) suggest that with
adequate testing in long-term bioassays, few
chemicals are likely to be considered non-
carcinogenic. Haseman (18) discusses the
low sensitivity of standard bioassays in
detecting weak carcinogens. Based on an
analysis of NTP studies by Gaylor (19), if
100 animals had been used per dose group
rather than 50 animals, with the resulting
increased power ofdetection and the same
incidence rates, it appears that at least 70%
ofNTP chemicals would be considered ani-
mal carcinogens. These results suggest that
the standard 2-year rodent bioassay
employing high-dose levels may, in effect,
be a long-term toxicity test in which cancer
is often one ofthe biologic manifestations,
limiting its usefulness as a good screen
forcarcinogenicity.
Our scientific knowledge about the
mechanisms ofcarcinogenesis is fardifferent
today than it was in the 1970s when the 2-
year bioassay was first adopted as a routine
screen. In addition to information from
genetic toxicity assays and structural alert
information, it is apparent today that a
broad range oftoxicologic and genetic toxic-
ity datawould be helpful in supporting pre-
dictions about the probable carcinogenicity
of a substance. Such information would
indude cell proliferation data, information
on apoptosis, peroxisome proliferation
capabilities, impact on hormonal profile,
production ofcz2p-globulin, profile of
metabolism, and otherinformation.
In summary, with the 2-year bioassay,
the rat-mouse prediction for carcinogenic-
ity is about 75% accurate. The bioassay is
poor at detecting the effect of weak car-
cinogensand is not useful for evaluation of
the mechanisms of carcinogenicity, an
array of information much more diverse
than anticipated when the bioassay was
first adopted over two decades ago. These
limitations raise obvious questions about
the usefulness of the bioassay as the gold
standard from which to draw conclusions
regarding alternatives to the 2-yearbioassay,
and must be considered as we move toward
accepting alternatives to the standard
rodent bioassay.
Alternative Strategies
Within the U.S. FDA, we have had con-
siderable discussion over the past 3 years
regarding the desire to develop a strategy
for carcinogenicity testing that would per-
mit regulatory decisions to be made on
data sets that may not include the results
oftraditional 2-year studies in both sexes
of two rodent species. Conclusions about
carcinogenic potential should be based on
a profile oftoxicologic data, not just on a
bioassay result. The weight ofevidence is
more important than an approach that
depends on a decision tree. Conclusions
should consider data that describe mecha-
nisms ofcarcinogenesis. One such strategy
might include use of data from new test
systems such as the transgenic models
TG:p53+/-, the p53 hemizygote, and the
transgenic model TG:AC. The relevancy
of the transgenic models to humans must
be evaluated. Another test system cur-
rently being reevaluated is the newborn
mouse assay.
A strategy that indudes the use ofthese
test systems is diagrammed in Figure 1.
Assuming there is human exposure and
therefore a desire to collect information
about carcinogenic potential, one would
base preliminary estimates on physical
chemical properties ofthe substance, struc-
tural alert information, information from
computer-based predictive systems, and the
results of the genetic toxicity screen. On
the basis of this information, one would
conclude that a substance is either non-
genotoxic or genotoxic. If the substance is
strongly genotoxic, one could conclude
that the chemical would be a carcinogen if
tested in a 2-year study, or the alternate
would be to proceedwith the 2-year rodent
study. However, because about one-third
of mutagens are not carcinogenic in the
standard bioassay and about one-third of
carcinogens are not mutagenic in common
tests, it probably would be prudent to
Human exposure
Yes No - nofurther studies
Physical-chemical properties
Structural alerts
Predictive system
Genetictoxicity screen
. l~~~~~~~~~~~~~~~~~~~~~
Nongenotoxic (screenfornongenotoxic mechanism)
Newborn mouse and/or TG:AC mouse
assay
Negative Positive Positive Negative
Assume 2-year study Assume
negative or presume negative
ifnegative for positive if if negative for
nongenotoxic mechanistic nongenotoxic
mechanisms evidence exists mechanisms
Genotoxic
Equivocal
TG p53+1-
Positive
2-yearstudy
or presume
positive
Strong positive
Presume
carcinogen
or2-yearstudy
Negative
TG:AC
Positive Negative
2-yearstudy Assume negative
or presume
positive
Figure 1. Example of a potential strategy.
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proceed with further testing. For genotoxic
chemicals, one might use the p53 hemi-
zygote as the next level ofscreen. Ifthis test
is positive, one has the option ofconduct-
ing a 2-year study to establish whether the
chemical is carcinogenic, or of presuming
that this genotoxicant is carcinogenic
because it was positive in the p53 hemizy-
gote, which is sensitive to genotoxic car-
cinogens. Ifthe substance is negative in the
p53 hemizygote, one might test in the
TG:AC to evaluate mechanisms ofcarcino-
genicity other than genotoxicity. Ifpositive
in this screen, one might assume that the
substance is carcinogenic or conduct a 2-
year study to clarify that potential. If the
substance is negative in the p53 hemizy-
gote and negative in the TG:AC strain, one
might be able to assume that this substance
is negative for carcinogenic potential.
For substances that are nongenotoxic,
one might proceed to either the newborn
mouse assay or to the TG:AC mouse. The
newborn mouse assay is included here
because of uncertainty at this point about
its range of predictiveness. Prior studies
have shown that this test is clearly sensitive
to genotoxicants; studies to evaluate its
ability to identify nongenotoxicants are
currently in progress. Nonetheless, if a
nongenotoxic chemical is positive in either
the TG:AC or the newborn mouse assay,
one has the option ofconducting a 2-year
study or presuming that the substance is
positive, particularly ifthere is mechanistic
evidence that the chemical might be a car-
cinogen by some nongenotoxic mecha-
nism. If the nongenotoxic chemical is
negative in the newborn mouse assay
and/or the TG:AC mouse, one might
assume that this chemical is not a carcino-
gen, particularly ifan evaluation ofmecha-
nisms for nongenotoxic carcinogenicity
reveals no evidence that this substance
would be carcinogenic through nongeno-
toxic mechanisms. Because this test system
provides tumor incidence rates, it is also
possible to consider the ratio of doses in
animals producing tumors to expected
human exposures. This ratio provides a
method for setting priorities for regulatory
action and further testing.
This test strategy, which includes
short-term in vivo screens for carcino-
genicity, also depends heavily on accumu-
lation of data that relate to nongenotoxic
mechanisms of carcinogenicity. This
indudes information on mechanisms iden-
tified in Table 1 that include hormone
modulation, perturbation ofgrowth factors,
changes in cell proliferation, apoptosis,
and other mechanisms of carcinogenicity
that do not depend upon primary damage
to DNA.
Further comments are warranted about
the feasibility of this test strategy for car-
cinogenicity. First, this is simply a concep-
tual framework from which a test strategy
could evolve. The strategy is not ready for
widespread implementation as a complete
test strategy at the present time because
some components have not been fully eval-
uated, and certainly not validated in the
traditional sense of formal acceptance of a
new test system. This raises the question,
however, ofwhat validation means when a
test system is mechanism based. To expend
considerable resources in multilaboratory
studies conducted on large numbers of
chemicals through blinded procedures to
confirm that a mechanism-based test sys-
tem does not detect carcinogens by other
mechanisms does not seem to be a useful
exercise. Some components of the strategy
presented in this paper will likely be
replaced or supplemented by others in the
future. Thus, mention of the newborn
mouse assay or specific transgenic systems
is not an endorsement that these are test
systems most likely to be in use several
years into the future.
There must be acceptance ofalternative
test systems by scientists in regulatory agen-
cies as well as in the regulated industry and
in academia for these test systems to be
important components of test systems in
the future. The development of the
Interagency Coordinating Committee on
theValidation ofAlternative Methods takes
us alongwaytoward that requirement.
One way to facilitate the acceptance of
new test systems would be to conduct
studies in parallel, using the traditional
2-year bioassay together with new test sys-
tems. This has been proposed many times
in the past and has not been implemented
to an appreciable extent because of the
significant costs involved. The NTP,
however, is currently supporting the fur-
ther evaluation of transgenic models
including the p53 hemizygote, the
TG:AC model, the rasH2 model, and the
newborn mouse assay. Other models are
being evaluated, including the Ep-pim-1
model, a TGFa model, and a Xeroderma
pigmentosum model. Still another multi-
laboratory evaluation is being conducted
on several ofthese systems through efforts
organized by International Life Sciences
Institute (20).
Table 1. Measures ofaltered cell function.
Hormone modulation
Steroid(estrogen, androgen, retinoid)
Growth factorperturbation
Cell proliferation (mitogenic, cytotoxic)
Specific tissue responses
Bladder, stones
Liver, necrosis
Kidney, a2p
Forestomach
Inhibition ofapoptosis
Specific mechanisms
5-Agonist, uterine tissue
H2-antagonist, glandular stomach
Peroxisome proliferation
Cell-to-cell communication
P450 induction
Spindlefibereffects
Altered methylation status
One other factor that impacts on the
acceptance ofalternative test systems is the
level ofreliance that we have placed on the
results of negative 2-year rodent studies in
the past. Through use ofthese bioassays for
over 25 years, we have derived a certain
level of confidence in the significance of
negative results in these tests. A major con-
cern about acceptance of alternative test
systems is how regulatory agencies will use
either positive or negative results from these
test systems. One must consider whether
we rely too heavily on the results of2-year
studies compared to our fear of using the
results ofnegative alternative studies.
Summary
The 2-year rodent bioassay as we have used
it for the past 25 years has been very useful,
but we recognize that it is not perfect. We
suggest that the 2-year bioassay has limited
usefulness as a standard for evaluation of
alternative test strategies. New test strate-
gies should be evaluated on their own
merit, as the 2-year bioassay has been over
the past 25 years. We are in a period of
transition during which results of short-
term tests, in conjunction with the results
of 2-year bioassays, will permit us the
opportunity to evaluate the performance of
these newshort-term tests. The recommen-
dations ofthe International Committee on
Harmonization to accept carcinogenicity
data in one species and other test systems
as an alternate to data from two rodent
species are evidence that, at least for drugs,
there is a desire to make changes in the
requirement for carcinogenicity data.
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